High-dose therapy with peripheral blood stem cell (PBSC) support is a frequently used treatment option in younger patients with poor prognosis histologically indolent (low-grade) non-Hodgkin's lymphoma (NHL), usually at the time of second or subsequent response to conventional-dose therapy. We have undertaken PBSC collection in 57 patients with histologically indolent NHL mobilized with either cyclophosphamide 1.5 g/m 2 or the ESHAP regimen, followed by daily G-CSF. Progenitor cell yields were determined by quantification of CD34 + cells and GM-CFC. Twelve patients (21%) failed to achieve the minimum progenitor cell requirements of 1 × 10 6 /kg CD34 + cells or 1 × 10 5 /kg GM-CFC in their pooled harvests and 40 patients (70%) failed to achieve the optimal harvest thresholds of 3.5 × 10 6 /kg CD34 + cells or 3.5 × 10 5 /kg GM-CFC. This high failure rate is significantly higher than that in patients with histologically aggressive NHL or Hodgkin's disease. A multivariate analysis was performed to identify factors contributing to the low stem cell yields in this group. This identified the time interval from the last chemotherapy to the priming chemotherapy as the most important predictive factor. With respect to CD34 and GM-CFC numbers, on the single harvest on the day the white cell count first exceeded 5 × 10 9 /l the P values were 0.0078 and 0.0065, respectively, and for the progenitor cell values on the pooled harvests the P values were 0.004 for CD34
patients with histologically aggressive NHL following relapse from first complete remission 1 and as consolidation during first complete remission in those patients with adverse prognostic features. 2 The role of such treatment intensification in the histologically indolent lymphomas is less clear and results from randomised controlled trials have not yet been reported. However, several non-randomised studies have suggested prolonged disease-free survival in patients with histologically indolent NHL who have received high-dose therapy with stem cell support, [3] [4] [5] [6] and such treatment intensification is increasingly used in younger patients.
Autologous bone marrow as a source of stem cells has been largely replaced by peripheral blood stem cells (PBSC) as this results in more rapid haematological regeneration [7] [8] [9] with attendant cost savings. 10 It is generally agreed that there are progenitor cell threshold requirements below which haemopoietic recovery can be severely delayed particularly for the platelet lineage. 11 In our institution we have defined the optimal threshold of CD34 + cells and GM-CFC as 3.5 ϫ 10 6 /kg and 3.5 ϫ 10 5 /kg, respectively, above which delayed haematological recovery is very unusual. 12 The minimum thresholds we have defined as 1 ϫ 10 6 /kg CD34 + cells or 1 ϫ 10 5 /kg GM-CFC, and recipients of less than these numbers of progenitor cells have a very high risk of delayed platelet recovery with some patients still platelet dependent beyond 1 year after transplantation. 13 In a previous study of pretreated patients with histologically aggressive NHL and Hodgkin's disease it was found that these minimum thresholds were achieved in approximately three-quarters of patients with just a single apheresis and in approximately 90% of patients if two harvests were pooled. 12 In the current study we report the results of PBSC collection in 57 patients with histologically indolent lymphomas and show that there is a statistically higher risk of collection failure. Multivariate analysis of possible contributory factors has indicated that this risk is particularly high in patients undergoing stem cell collection soon after receiving a previous course of treatment.
Patients and methods

Patient population
Fifty-seven patients with a diagnosis of a low-grade lymphoma as defined in the Working Formulation 14 underwent PBSC collection at University College London Hospitals (UCLH) between January 1994 and September 1996. Characteristics of the patients are shown in Table 1 . Thirteen patients had suffered from high-grade transformation prior to harvesting. Twenty-four patients had a history of prior bone marrow involvement, but none had demonstrable bone marrow disease at the time of harvesting as determined by morphological assessment of a trephine biopsy. Most patients were heavily pretreated, having received a median of 11 cycles of chemotherapy. In patients receiving continuous or intermittent chlorambucil each month of therapy was considered as one cycle.
Stem cell mobilization and collection
Two mobilization regimens were used. Fifty patients underwent mobilization with cyclophosphamide and G-CSF, as previously described. 15 Low-dose cyclophosphamide (1.5 g/m 2 ) was given intravenously on day 1, followed by G-CSF given subcutaneously at 10 g/kg (filgrastim) or a single vial of lenograstim (263 g) 24 h afterwards, and daily thereafter until mobilization was complete. Seven patients underwent an alternative mobilization regimen with ESHAP 16 (etoposide 40 mg/m 2 i.v. days 1-4; methylprednisolone 500 mg i.v. days 1-5; cytarabine 2 g/m 2 day 1, and cisplatin 25 mg/m 2 days 1-4), followed by 263 g lenograstim daily, from day 6 to completion of harvest. Forty-eight patients were apheresed on a Baxter CS3000 (Baxter Healthcare, Berkshire, UK) set to process a fixed 10 l blood volume. The remaining nine patients were collected on a COBE Spectra (COBE Laboratories, Gloucester, UK) and 10-15 l of blood processed (median 12.3 l). We have previously shown in a larger study that the per- formance of these two machines is very similar. 12 One to three apheresis harvests were collected, the number of aphereses being determined by the progenitor yields obtained.
Progenitor evaluation
A sterile sample from each harvest was diluted 1/10 and 1/100 in RPMI containing 10% fetal calf serum and 20 U/ml heparin. Harvest CD34-positive cell numbers were determined by APAAP (alkaline phosphatase-anti-alkaline phosphatase) staining of harvest product smears or by flow cytometry, as previously described. 12 Granulocyte/ monocyte-colony forming cells (GM-CFC) were evaluated in a methylcellulose-based clonogenic assay medium containing 10% 5637 CM and 2.5 I U/ml rHEpo as previously described, 12 or using commercially available media (StemCell Technologies, Metachem, Northampton, UK) with added recombinant growth factors (stem cell factor 10 ng/ml, IL-3 30 ng/ml, GM-CSF 25 ng/ml and erythropoietin 3 U/ml). Harvest specimens were plated in triplicate at concentrations of 2.5 ϫ 10 4 /ml. Colonies were counted after 14 days incubation at 37°C in humidified CO 2 .
Analysis of factors predicting for progenitor cell yield
Univariate and multivariate analyses were performed to determine parameters potentially influencing PBSC yields using the hazards regression model of Cox. 17 Analysis was performed for the following factors: age, sex, high-grade transformation or element of disease, previous bone marrow involvement, prior radiotherapy, total chemotherapy received (priming chemotherapy excluded), previous treatment with chlorambucil, fludarabine and miniBEAM (carmustine 60 mg/m , priming regimen and length of time between last chemotherapy received and mobilization. Two patients did not receive chemotherapy prior to mobilization, and were not included in the prognostic factors analysis. The analysis was performed for the total number of progenitor cells (CD34 + cells and GM-CFC) collected and for the first harvest only on the day the peripheral leukocyte count first exceeded 5.0 ϫ 10 9 /l. This has previously been shown to be the day that progenitor collections are usually optimal 12 and is not influenced by the number of aphereses performed which could confound the analysis of total progenitor cells collected. The harvest on this day is referred to as the 'primary harvest'. In seven cases, a leukocyte count of 5.0 ϫ 10 9 /l was not achieved during the predicted period for optimal apheresis, and the best yields for these seven patients were taken as 'primary harvest' values.
Results
Progenitor cell yields
Twenty-seven patients (47%) failed to achieve the minimum requirement of either 1 ϫ 10 6 /kg CD34 + cells or 1 ϫ 10 5 /kg GM-CFC on the primary harvest and 12 patients (21%) failed to achieve either of these targets after pooling of up to three harvests (Table 2) . It should be noted that not all patients who mobilized poorly received three harvests, as the PBSC collection was abandoned in some patients if the initial yields were very poor and there was no evidence of a marked rise in circulating CD34
+ cells. The proportion of patients attaining the optimal harvest of 3.5 ϫ 10 6 /kg CD34 + cells or 3.5 ϫ 10
5
/kg GM-CFC on the primary or pooled harvests were only 23% and 30% respectively. The proportion of patients achieving a collection of Ͼ2 ϫ 10 6 /kg CD34 + cells or Ͼ2 ϫ 10 5 /kg was 28% and 35%, respectively, for the primary and pooled harvests. This value is presented as it approximates to the number of progenitor cells required if stem cell purification is to be performed allowing for 50% losses during the procedure. 18 For comparison, previously published 12 data is presented in Table 2 on the proportion of patients with histologically aggressive NHL and Hodgkin's disease who achieve these thresholds. On the primary harvest the proportion of patients achieving the minimal CD34 threshold or twice this number was highly significantly less in the low-grade lymphoma patients. The proportion of patients with low-grade lymphoma achieving the optimal threshold on this single harvest was also less than in the high-grade NHL/HD patients but this was not statistically significant. When pooled harvests are considered the proportion of patients achieving the minimum threshold is no longer statistically significant, but among the low-grade lymphomas there is a highly significant reduction in the proportion of patients achieving the minimum threshold required for CD34
+ cell selection and for the optimal threshold ( Table 2) .
Analysis of factors predicting for progenitor cell yield
On univariate analysis (Table 3) , the only significant factor influencing CD34 (pooled total), CD34 (primary harvest) and GM-CFC (primary harvest) was the time between previous chemotherapy and mobilization, higher yields being obtained with a longer interval between the two. The overall time since diagnosis to harvest was not predictive of yield. For GM-CFC (total) there was a trend for yields to be affected by previous radiotherapy, as well as the time Table 2 Comparison of the proportion of PBSC collections meeting minimal, CD34 + cell selection and optimal progenitor thresholds in patients with low-grade (LG NHL) vs those with high-grade (HG NHL) or Hodgkin's disease (HD) from previous therapy to mobilization. On multivariate analysis (Table 2) , the time from chemotherapy to mobilization remained significant throughout; prior radiotherapy lost significance for GM-CFC (total).
To determine at what interval between chemotherapy and mobilization a significant difference was obtained, patients were grouped into those with 2, 3, 4 and 6 months or less between chemotherapy and mobilization, and those with a greater interval than 2, 3, 4 and 6 months, respectively. The difference became significant at 6 months for total CD34 /kg for those delayed six months or more. None of the 11 patients in whom there was an interval of 6 months or more postchemotherapy before undergoing mobilization failed to achieve acceptable total CD34
+ cell yields, compared to 26% of the 46 patients who were harvested earlier.
Discussion
The importance of obtaining adequate numbers of stem cells to enable rapid engraftment after high-dose therapy has been demonstrated in several studies.
7-9,12,13 Acceptable yields vary from centre to centre, a variation that may be partly accounted for by differences in methods used to establish CD34
+ cell numbers and GM-CFC and partly because different definitions of adequacy are employed. In our institution we have defined both minimum and optimal thresholds and it is our practice not to proceed to high-dose therapy if less than the minimum number of CD34 + cells or GM-CFC are collected. 12, 13 In addition we have adopted a threshold of twice the minimum values before proceeding to stem cell purification, a procedure that is of possible value as an initial purging procedure for low-grade lymphomas. 19 A proportion of patients fail to achieve even the minimum thresholds with pooled harvests and in this report we demonstrate that this proportion is significantly higher in pretreated patients with low-grade lymphomas than those with pretreated high-grade lymphomas or Hodgkin's disease. A single leukapheresis, on the day the white cell count exceeds 5.0 ϫ 10 9 /l, is thus inadequate in almost half the patients with low-grade NHL, compared to 17% of those with high-grade NHL or Hodgkin's disease. Pooling of harvests achieves optimal stem cell numbers in the majority (69%) of patients with high-grade lymphomas or Hodgkin's disease, but only the minority of low-grade NHL patients (30%). This means that of those low grade lymphoma patients who are able to undergo PBSC transplant (more than the minimum progenitor cell thresholds achieved), most will be at risk of delayed platelet engraftment. Moreover, only 35% of total PBSC collections from this group would be eligible for CD34
+ cell selection even if harvests are pooled.
There are several possible reasons why progenitor cell yields might be reduced in low-grade lymphomas. First the incidence of overt and occult bone marrow disease is undoubtedly higher in low-grade lymphomas and it is possible that this results in some residual damage to the bone marrow. However, all patients were free of gross bone marrow disease at the time of mobilization and the presence of previous overt marrow disease did not predict for a poor progenitor cell yield. Second, the patients with low-grade lymphomas had received more cycles of prior chemotherapy than our previously reported patients with histologically aggressive lymphomas and Hodgkin's disease. 12 Several groups have shown that the number of cycles of previous chemotherapy was predictive of progenitor cell yield 20, 21 but this was not apparent in our series of patients with histologically aggressive NHL and Hodgkin's disease, nor is it a significant predictive factor in this series of patients with low-grade NHL. This may be because of the relative homogeneity of patients within a particular disease group treated at our centre compared to some other series. A third possibility is that patients with low-grade lymphomas are more likely to have received previous radiotherapy which we 12 and others 20, 22 have previously shown has a negative impact on progenitor cell mobilization. However, only 12/57 (21%) patients had had previous radiotherapy in this series which is less than the 35/101(35%) in our patients with histologically aggressive NHL and Hodgkin's disease. Fourth, it is possible that the drugs used to treat low-grade NHL are more stem cell toxic than those used in other forms of lymphoma. In the multivariate analysis neither chlorambucil (either any chlorambucil or Ͼ3 months treatment with chlorambucil) nor fludarabine, the two most frequently used regimens, appeared as a significant predictive factor although it is possible that both agents are highly toxic to the stem cell compartment. In this series 58% of patients had received prior chorambucil, 32% had received fludarabine and 24% had received neither drug.
The univariate and multivariate analysis of factors predicting for stem cell yield in this series indicated that the duration between chemotherapy and mobilization significantly affected the yield of progenitor cells obtained. A similar correlation was previously shown by Kotasek et al, 23 although not in two other studies. 20, 24 These studies, however, grouped patients into those with shorter and longer delays to mobilization, with cut-offs at 2-3 months; one study, in fact, demonstrated a trend towards better yields after 2 months delay. 19 In this series of low-grade lymphoma patients, the delay only becomes significant with 6 months or more between chemotherapy and mobilization. It is possible that the delay between previous chemotherapy and PBSC mobilization allows repair of a damaged marrow from stem cell toxic therapy. If this is the case it must be borne in mind that repair of the CD34 + cell and GM-CFC populations might exceed that in the repopulating stem cell compartment 25 a situation that might be clinically relevant if patients are treated with highly myeloablative therapy such as total body irradiation. An alternative possibility is that those patients who do not have a long interval between previous therapy and stem cell mobilization are more likely to have aggressive disease and this somehow affects the quality of the marrow.
Given the failure to collect adequate stem cells in over 20% of patients with low-grade lymphoid malignancies, and suboptimal collections in 70%, any change in timing of mobilization that improves stem cell yield should perhaps be considered. Waiting 6 months after chemotherapy may prove beneficial in terms of progenitor cell yield, although this approach carries the risk of disease recurrence or progression in the interim period. Another approach would be to harvest patients at an earlier stage of the disease, either in an established first remission when immediate high-dose therapy is not planned or coincident with the initial therapy in those patients with no overt bone marrow involvement at diagnosis. Harvests could then be retained in storage for possible future use, although this would impose considerable logistic problems. Finally we believe that pretreated patients with low-grade lymphomas should be considered for alternative mobilization regimens that might include higher doses of priming chemotherapy, higher doses of G-CSF or the use of additional cytokines.
